Drug Trial Radar · NCT04646759
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
516
Planned (sponsor's estimate)
Start
Oct 14, 2020
Primary completion
Dec 14, 2028
Study completion Dec 14, 2030
Sponsor
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and HER2 inhibitor pyrotinib have a synergistic effect. The preliminary analysis of our prospective shows that the efficacy is close to that of capecitabine combined with pyrotinib, and the adverse events are significantly improved compared with capecitabine combined with pyrotinib. Therefore, it is necessary to further carry out a head-to-head phase III randomized controlled clinical trial to study the efficacy and safety of fulvestrant combined with pyrotinib in the treatment of HR + / HER2 + advanced breast cancer.
Conditions
- Breast Cancer
Interventions
Fulvestrant combined with PyrotinibDrug
Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
Capecitabine combined with PyrotinibDrug
Capecitabine 1000mg/m\^2 bid d1-d14,every 21 days Pyrotinib 400mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 24 months
- Incidence of grade 3 hand foot syndrome (rate)Time frame: From the date of enrollment to one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.